PTEN Recombinant Rabbit Monoclonal Antibody Product Datasheet Catalog# BX50306 Clone# BP6283 Predicted Molecular Wt: 54kDa Purity: ProA affinity purified IgG Species Cross-reactivity: Human Form: Liquid Applications: IHC-P Swissprot ID: P60484 Background: PTEN acts as a dual-specificity protein phosphatase, dephosphorylating tyrosine-, serine- and threonine-phosphorylated proteins. Tumor suppressor, the lipid phosphatase activity is critical for its tumor suppressor function. Antagonizes the PI3K- AKT/PKB signaling pathway by dephosphorylating phosphoinositides and thereby modulating cell cycle progression and cell survival. The unphosphorylated form cooperates with MAGI2 to suppress AKT1 activation. PTEN gene is a tumor suppressor gene that maps to chromosome 10q23. PTEN is the first oncogene with bispecific phosphatase activity discovered in humans, regulating tumour cell growth, apoptosis and migration, etc. PTEN is found to be inactivated in a variety of tumours, and its inactivation is due to methylation modifications in addition to common mutations. High-grade endometrioid carcinomas are commonly deficient in PTEN expression. PTEN gene deletion has also been found in glioblastoma, prostate cancer, melanoma, and breast cancer. Subcellular location: Cytoplasm ， Nucleus Recommended Method: Heat induced epitope retrieval with Tris-EDTA buffer (pH 9.0), primary antibody incubate at RT (18°C-25°C) for 30 minutes. Immunogen: Synthetic peptide. This information is proprietary to Biolynx. Storage Buffer: PBS 59%, Sodium azide 0.01%, Glycerol 40%, BSA 0.05%. Storage Conditions: -25°C to -18°C Shipment Instructions: Shipped on blue ice. Upon delivery store at -25°C to -18 °C. Avoid freeze / thaw cycles. Recommended Dilution: IHC-P: 1:100-1:200 Background References: 1. Song M.S. et al. Nature 455:813-817. 2. Stohr N. et al. Genes Dev. 26:176-189 Immunohistochemical (formalin/PFA-fixed paraffin- embedded sections) analysis of human endometrial carcinoma labelled with PTEN using BP6283.
杭州浩克生物
您好！请登录